-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Bu2CSVLAe62Tbv+qjKc/QcEmTLHolF/6dqtZrkn9m+Hekk2R9/19CeeRfO0i0dve HO6rv5oRL3J9ka69CkLz1w== 0001179110-04-009133.txt : 20040429 0001179110-04-009133.hdr.sgml : 20040429 20040429121852 ACCESSION NUMBER: 0001179110-04-009133 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040401 FILED AS OF DATE: 20040429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BALEZENTIS CARL W CENTRAL INDEX KEY: 0001286811 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30981 FILM NUMBER: 04763499 MAIL ADDRESS: STREET 1: C/O GENAISSANCE PHARMACCUTICALS INC STREET 2: FIVE SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENAISSANCE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001110009 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 061338846 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FIVE SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 2037731450 MAIL ADDRESS: STREET 1: FIVE SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 edgar.xml FORM 4 - X0202 4 2004-04-01 0 0001110009 GENAISSANCE PHARMACEUTICALS INC GNSC 0001286811 BALEZENTIS CARL W C/O GENAISSANCE PHARMACEUTICALS, INC. NEW HAVEN CT 06511 0 1 0 0 SVP & President, Lark Stock option (right to buy) 3.49 2004-04-01 4 A 0 100000 3.49 A 2008-04-01 2014-04-01 Common Stock 100000 100000 D Stock Option (right to buy) 0.66 2004-04-01 4 A 0 31675 A 2004-10-30 2010-10-30 Common Stock 31675 31675 D Stock Option (right to buy) .66 2004-04-01 4 A 0 31675 A 2005-07-13 2011-07-13 Common Stock 31675 31675 D Stock Option (right to buy) .66 2004-04-01 4 A 0 63350 A 2005-09-05 2011-09-05 Common Stock 63350 63350 D Stock Option (right to buy) .66 2004-04-01 4 A 0 108600 A 2006-01-01 2012-01-01 Common Stock 108600 108600 D Stock Option (right to buy) .88 2004-04-01 4 A 0 58186 A 2007-03-03 2013-03-03 Common Stock 58186 58186 D This option vests quarterly over 4 years. Dr. Balezentis received this option in the merger among the issuer, Brown Acquisition Corp and Lark Technologies, Inc. (the "Merger") in exchange for an option to purchase 17,500 shares of Lark Technologies common stock for $1.19 per share. This stock option provides for vesting of 25% of the original number of shares on the anniversary of the option grant over a four year period with the final vesting on October 30, 2004. Dr. Balezentis received this option in the Merger in exchange for an option to purchase 17,500 shares of Lark Technologies common stock for $1.19 per share. This stock option provides for vesting of 25% of the original number of shares on the anniversary of the option grant over a four year period with the final vesting on July 31, 2005. Dr. Balezentis received this option in the Merger in exchange for an option to purchase 35,000 shares of Lark Technologies common stock for $1.19 per share. This stock option provides for vesting of 25% of the original number of shares on the anniversary of the option grant over a four year period with the final vesting on September 5, 2005. Dr. Balezentis received this option in the Merger in exchange for an option to purchase 60,000 shares of Lark Technologies common stock for $1.19 per share. This stock option provides for vesting of 25% of the original number of shares on the anniversary of the option grant over a four year period with the final vesting on January 1, 2006. Dr. Balezentis received this option in the Merger in exchange for an option to purchase 32,147 shares of Lark Technologies common stock for $1.59 per share. This stock option provides for vesting of 25% of the original number of shares on the anniversary of the option grant over a four year period with the final vesting on March 3, 2007. /s/ Carl W. Balezentis 2004-04-29 -----END PRIVACY-ENHANCED MESSAGE-----